Low costs and short waiting times for conducting clinical research are the main reasons why pharmaceutical firms transfer their trials to Poland, according to an analysis drafted by A.T. Kearney.Poland’s main advantages in terms of its attractiveness as a centre for clinical trials are its relatively large population, which facilitates a high recruitment rate, its legal environment, and its scientific and technical base. Poland was ranked eighth in the Country Attractiveness Index for Clinical Trials ranking prepared by A.T. Kearney.
